Quarterly ResultMay 12, 2026, 04:38 PM
Xenetic Biosciences Q1 Net Loss Narrows to $0.46M; Initiates Strategic Review
AI Summary
Xenetic Biosciences reported a narrowed net loss for the first quarter of 2026, reaching $456,382, a significant improvement from $903,141 in the prior year. This was supported by an increase in royalty revenue to $806,923. Concurrently, the company announced the initiation of a formal strategic review process to explore options for maximizing shareholder value, including potential sale or business combination. Despite financial improvements, the company anticipates needing additional long-term capital.
Key Highlights
- Q1 2026 net loss narrowed to $456,382 from $903,141 in Q1 2025.
- Royalty revenue increased to $806,923 in Q1 2026 from $593,261 in Q1 2025.
- Basic and diluted net loss per share improved to $(0.20) from $(0.59) year-over-year.
- Net cash used in operating activities decreased to $536,377 from $1,001,892.
- Cash balance as of March 31, 2026, was $7,347,255.
- Company initiated a formal strategic review process to maximize shareholder value.
- Extended and expanded Scripps Research agreement with additional funding up to $0.5 million.